Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Make your likes visible on Facebook?

Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.

No, thanks

Pharmaceutical Research Manufacturers of American (PhRMA)

No description
by

Isabelle Kerner

on 1 April 2016

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Pharmaceutical Research Manufacturers of American (PhRMA)

Type of Group
Economic group
Trade Group
Represents the interests of its members who are all companies who operate within the pharmaceutical industry
Material Incentives
PhRMA provides its members with lobbyists, advertises on behalf of its members, and runs public relations campaigns that promote a positive public opinion of its members
Influence in Health Policies
Medicare Modernization Act of 2003
Lobbying expenditures doubled between 2000 and 2002
Lobbied congress to ensure that the expansion of Medicare Part D would prohibit Medicare from negotiating prices
Ensured that the reimportation ban on prescription drugs would remain in place
Members
48 member comanpies all of which are top prpducing pharmaceutical companies
15 'research associates'
Influence in Health Policies
Patient Protection and Affordable Care Act of 2010
Would not have passed without PhRMA's support
$80 billion deal led by former representative Billy Tauzin
$80 billion over 10 years in prescription drug savings in return for guarentee the White House would block any legislation that granted Medicare negotiating power or lifted the reimportation ban
Deal passed though Senate on Christmas Eve 2009
Pharmaceutical Researchers and Manufacturers of America (PhRMA)
Lobbying
At least 20 government affairs employees
Probably 20-35
Also hire outside lobbying firms
Most of PhRMA's lobbyists have worked in either the executive or legislative branches of government
Have spent about $15 million so far in 2015
Lobbying Expenditures by Year
Pharmaceutical Research Manufacturers of American (PhRMA)
"PhRMA's mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical and biotechnology research companies."
Research Associates vs. Members
Research associates are smaller members
Smaller members are pre-market companies
Pre-market companies are those getting ready to enter phase 3, the clinical research phase of drug development
Influence in Trade Policy
Trans-Pacific Trade Partnership (TPP)
Lobbied White House and Congress for 12 years of data protection on biologics
So far they only get 7
Many believe that US negotiators have been too concerned with PhRMA's priorities
Doctors Without Borders has warned the agreement will increase drug prices
Intellectual Property Laws
America Invents Act of 2011
Changed patent review system fom inter partes re-examination to inter partes review
Favors challenger of the patent
PhRMA is lobbying Congress asking to be carved out of the process
Want patents challenged in the district court
Power and Influence
One of the most economically and politically powerful interest groups in the U.S.
Influenced legislation in order to protect profits
Other sectors of the healthcare industry have failed
Sixth in lobbying expenditures
Rising prescription drug prices
80% of net top 20 drug company's profits due to price increases in 2014
US spending on presription drugs increased by 13% between 2013 and 2014
Broad patient access to safe and effective medicines through a free market, without price controls;
Strong intellectual property incentives;
And transparent, effective regulation and a free flow of information to patients.
Full transcript